TNFSF10 and type 1 diabetes mellitus: Subsequent studies demonstrated that TRAIL inhibited the proliferation of diabetogenic T-cells [7], and that the development and progression of T1DM were reduced by adenovirus-mediated TRAIL delivery into pancreatic islets [8], or by treatment with recombinant TRAIL [9].